| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cancer novel
|
Murdy, Abigail Grace
|
|
2016
|
17 |
9 |
p. 1201-
1 p.
|
artikel
|
| 2 |
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
|
Rini, Brian I
|
|
2016
|
17 |
9 |
p. 1317-1324
8 p.
|
artikel
|
| 3 |
Are sarcomas hereditary?
|
Benjamin, Robert S
|
|
2016
|
17 |
9 |
p. 1179-1181
3 p.
|
artikel
|
| 4 |
Are we there yet? Prolonged MAPK inhibition in BRAF V600-mutant melanoma
|
Khushalani, Nikhil I
|
|
2016
|
17 |
9 |
p. 1178-1179
2 p.
|
artikel
|
| 5 |
Asbestos concerns in Australian buildings
|
Burki, Talha Khan
|
|
2016
|
17 |
9 |
p. e377-
1 p.
|
artikel
|
| 6 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
|
Zielinski, Christoph
|
|
2016
|
17 |
9 |
p. 1230-1239
10 p.
|
artikel
|
| 7 |
Beyond Epstein-Barr virus: genetic predisposition of natural killer T-cell lymphoma
|
Reddy, Nishitha M
|
|
2016
|
17 |
9 |
p. 1176-1177
2 p.
|
artikel
|
| 8 |
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study
|
Villani, Anita
|
|
2016
|
17 |
9 |
p. 1295-1305
11 p.
|
artikel
|
| 9 |
Brentuximab vedotin for CD30-positive tumours
|
Masuda, Shigeo
|
|
2016
|
17 |
9 |
p. e371-
1 p.
|
artikel
|
| 10 |
Cancer overtakes heart disease as biggest killer in 12 countries
|
Tanday, Sanjay
|
|
2016
|
17 |
9 |
p. e382-
1 p.
|
artikel
|
| 11 |
Challenges in breast and cervical cancer control in Japan
|
Hanley, Sharon J B
|
|
2016
|
17 |
9 |
p. e372-
1 p.
|
artikel
|
| 12 |
Clinton and Trump: competing visions for the Affordable Care Act and US health care
|
Furlow, Bryant
|
|
2016
|
17 |
9 |
p. 1197-1198
2 p.
|
artikel
|
| 13 |
Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|
Ascierto, Paolo A
|
|
2016
|
17 |
9 |
p. 1248-1260
13 p.
|
artikel
|
| 14 |
Comedians deliver serious messages at Edinburgh Festival Fringe
|
Ranscombe, Peter
|
|
2016
|
17 |
9 |
p. 1201-1202
2 p.
|
artikel
|
| 15 |
Correction to Lancet Oncol 2015; 16: e539
|
|
|
2016
|
17 |
9 |
p. e373-
1 p.
|
artikel
|
| 16 |
Correction to Lancet Oncol 2016; 17: e335
|
|
|
2016
|
17 |
9 |
p. e373-
1 p.
|
artikel
|
| 17 |
Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study
|
Bhakta, Nickhill
|
|
2016
|
17 |
9 |
p. 1325-1334
10 p.
|
artikel
|
| 18 |
Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment
|
Aznar, Marianne C
|
|
2016
|
17 |
9 |
p. 1189-1190
2 p.
|
artikel
|
| 19 |
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study
|
Wallington, Michael
|
|
2016
|
17 |
9 |
p. 1203-1216
14 p.
|
artikel
|
| 20 |
Delayed systemic treatment in metastatic renal-cell carcinoma
|
Russo, Paul
|
|
2016
|
17 |
9 |
p. 1187-1189
3 p.
|
artikel
|
| 21 |
Delirium in patients with advanced cancer
|
Carlson, Bob
|
|
2016
|
17 |
9 |
p. e379-
1 p.
|
artikel
|
| 22 |
Differences in availability of cancer drugs across Europe
|
Mayor, Susan
|
|
2016
|
17 |
9 |
p. 1196-
1 p.
|
artikel
|
| 23 |
Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial
|
Sultan, Ahmed A
|
|
2016
|
17 |
9 |
p. 1217-1229
13 p.
|
artikel
|
| 24 |
Do cancer survival statistics for every hospital make sense?
|
Morris, Melanie
|
|
2016
|
17 |
9 |
p. 1192-1194
3 p.
|
artikel
|
| 25 |
EANO guidelines for the diagnosis and treatment of meningiomas
|
Goldbrunner, Roland
|
|
2016
|
17 |
9 |
p. e383-e391
nvt p.
|
artikel
|
| 26 |
England's 30-day chemotherapy mortality: a measure of quality of care?
|
Cameron, David
|
|
2016
|
17 |
9 |
p. 1172-1173
2 p.
|
artikel
|
| 27 |
Gene mutation linked to familial Barrett's oesophagus
|
Das, Manjulika
|
|
2016
|
17 |
9 |
p. e378-
1 p.
|
artikel
|
| 28 |
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study
|
Li, Zheng
|
|
2016
|
17 |
9 |
p. 1240-1247
8 p.
|
artikel
|
| 29 |
Imaging oligometastatic cancer before local treatment
|
Franklin, James M
|
|
2016
|
17 |
9 |
p. e406-e414
nvt p.
|
artikel
|
| 30 |
Improvement of outcomes for TP53 carriers
|
Plon, Sharon E
|
|
2016
|
17 |
9 |
p. 1184-1186
3 p.
|
artikel
|
| 31 |
Ipilimumab for relapse after allogeneic transplantation
|
Baker, Holly
|
|
2016
|
17 |
9 |
p. e374-
1 p.
|
artikel
|
| 32 |
Is nivolumab an option for Hodgkin's lymphoma?
|
Gisselbrecht, Christian
|
|
2016
|
17 |
9 |
p. 1183-1184
2 p.
|
artikel
|
| 33 |
Is there room for bevacizumab in metastatic breast cancer?
|
Brufsky, Adam
|
|
2016
|
17 |
9 |
p. 1175-1176
2 p.
|
artikel
|
| 34 |
IVF treatment not linked to breast cancer
|
Tanday, Sanjay
|
|
2016
|
17 |
9 |
p. e375-
1 p.
|
artikel
|
| 35 |
Measuring the quality of cancer care in UK hospitals
|
The Lancet Oncology,
|
|
2016
|
17 |
9 |
p. 1171-
1 p.
|
artikel
|
| 36 |
Miss Sharon Jones
|
Burki, Talha Khan
|
|
2016
|
17 |
9 |
p. 1199-
1 p.
|
artikel
|
| 37 |
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|
Ballinger, Mandy L
|
|
2016
|
17 |
9 |
p. 1261-1271
11 p.
|
artikel
|
| 38 |
Mutated BRAF and personalised medicine in differentiated thyroid cancer
|
Bible, Keith C
|
|
2016
|
17 |
9 |
p. 1181-1183
3 p.
|
artikel
|
| 39 |
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
|
Younes, Anas
|
|
2016
|
17 |
9 |
p. 1283-1294
12 p.
|
artikel
|
| 40 |
Other People
|
David, Rachel
|
|
2016
|
17 |
9 |
p. 1200-
1 p.
|
artikel
|
| 41 |
Patient safety and institutional review boards in multi-institutional dose escalation or expansion trials
|
Jones, Roy B
|
|
2016
|
17 |
9 |
p. 1190-1191
2 p.
|
artikel
|
| 42 |
Photochemical internalisation for solid malignancies
|
Madsen, Steen
|
|
2016
|
17 |
9 |
p. 1173-1174
2 p.
|
artikel
|
| 43 |
Physical exercise might affect breast cancer outcomes
|
Balakrishnan, Vijay Shankar
|
|
2016
|
17 |
9 |
p. e380-
1 p.
|
artikel
|
| 44 |
Postoperative radiotherapy for paediatric medulloblastoma
|
Burki, Talha Khan
|
|
2016
|
17 |
9 |
p. e381-
1 p.
|
artikel
|
| 45 |
Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis
|
Asdourian, Maria S
|
|
2016
|
17 |
9 |
p. e392-e405
nvt p.
|
artikel
|
| 46 |
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
|
Saad, Fred
|
|
2016
|
17 |
9 |
p. 1306-1316
11 p.
|
artikel
|
| 47 |
Radium-223 in prostate cancer: emitting the right signals
|
Madan, Ravi A
|
|
2016
|
17 |
9 |
p. 1186-1187
2 p.
|
artikel
|
| 48 |
Resistance to PD-1 blockade in melanoma
|
Burki, Talha Khan
|
|
2016
|
17 |
9 |
p. e376-
1 p.
|
artikel
|
| 49 |
9th International Conference on Head and Neck Cancer
|
Collingridge, David
|
|
2016
|
17 |
9 |
p. 1195-
1 p.
|
artikel
|
| 50 |
Vemurafenib in patients with BRAF V600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
|
Brose, Marcia S
|
|
2016
|
17 |
9 |
p. 1272-1282
11 p.
|
artikel
|
Tijdschrift beschrijving